How Ozempic and Wegovy turned Novo Nordisk into a $400 billion company

How Ozempic and Wegovy turned Novo Nordisk into a 0 billion company


Danish drugmaker Novo Nordisk has entered a new chapter in its 100-year history — thanks to its newfound success with two products: Ozempic and Wegovy. 

The drugs are once-weekly injectables of a medication called semaglutide, prescribed for Type 2 diabetes and weight loss. Their skyrocketing popularity has boosted Novo Nordisk to new heights.

Novo Nordisk’s share price has more than quadrupled in the past five years, making it Europe’s most valuable company by market cap.

“It’s clear that nobody had expected that it would be taking off this quickly,” said Novo Nordisk CEO Lars Fruergaard Jørgensen in August. “We all along knew that obesity was a serious chronic disease also when most others did not see it like that. So we knew we were onto something big.”

In 2018, the first full year with Ozempic on the market, Novo Nordisk’s net sales were 111.8 billion Danish krone, or $17.7 billion, using an average exchange rate at the time. 

In the last three months of 2022, U.S. health-care providers wrote more than 9 million prescriptions for Ozempic, Wegovy and other diabetes and obesity drugs, according to analytics firm Trilliant Health. 

Ozempic accounted for more than 65% of total prescriptions as of the end of 2022.

And it was only up from there: In the first six months of 2023, sales of Ozempic and Wegovy rose by 58% and 363%, respectively.   

“There has not been any performance near what we’ve seen over the last year or two,” said Jared Holz, health care sector specialist at Mizuho, adding that semaglutide alone could be worth up to $300 billion annually over time.

Semaglutide falls under a drug class called GLP-1 agonists, which mimic GLP-1 receptors in the body and produce more insulin, helping to lower blood sugar levels and decrease appetite. 

Novo Nordisk’s treatments are not the only GLP-1 treatments available, but they are the only semaglutide products currently on the U.S. market, as the company holds a patent until 2032.

Eli Lilly has developed its own GLP-1 drug, tirzepatide, marketed as Mounjaro, and other companies, such as Pfizer, are creating their own injectables. Mounjaro is not yet approved by the Food and Drug Administration. 

Watch the video to learn more.



Source

Healthy Returns: What to know about the FDA’s plan to speed up some drug reviews
Health

Healthy Returns: What to know about the FDA’s plan to speed up some drug reviews

FILE PHOTO: The headquarters of the U.S. Food and Drug Administration (FDA) is seen in Silver Spring, Maryland November 4, 2009.  Jason Reed | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The Food […]

Read More
Taking on Goliath: Brain surgeon’s clash with UnitedHealthcare shows insurer’s hardball tactics
Health

Taking on Goliath: Brain surgeon’s clash with UnitedHealthcare shows insurer’s hardball tactics

Dr. Catherine Mazzola, a pediatric neurosurgeon, runs a practice she says is in serious jeopardy because of recent moves by UnitedHealth Group. Zach Gross for NBC News Dr. Catherine Mazzola, a pediatric neurosurgeon, runs a practice in New Jersey that treats low-income children on Medicaid. Since 2008, she has cared for boys and girls with cerebral palsy, […]

Read More
FDA approves Gilead’s twice-yearly HIV prevention injection, offering a powerful and convenient new option
Health

FDA approves Gilead’s twice-yearly HIV prevention injection, offering a powerful and convenient new option

The logo of Gilead Sciences pharmaceutical company is seen in Oceanside, California, April 29, 2020. Mike Blake | Reuters The Food and Drug Administration on Wednesday approved Gilead’s twice-yearly antiviral injection for preventing HIV – a milestone that the company and some experts say could help bring the world closer to ending the decades-long epidemic […]

Read More